Apposite Capital

Kelso Pharma is an innovative pharmaceutical manufacturing company focused on improving patient outcomes through the development and distribution of branded medications. By prioritizing cost-effectiveness, Kelso Pharma aims to meet the diverse needs of patients, helping them recover from various illnesses. The firm is dedicated to enhancing the healthcare market by providing high-quality medications designed to benefit patients and support their health and well-being.

Mirada Medical Limited is a developer of medical imaging software applications, enhancing patient outcomes in radiology, molecular imaging, radiation oncology, and multidisciplinary meetings across hospitals, imaging centers, and cancer centers. The company offers several key products, including Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which provides automated organ-at-risk contouring services; and Mirada IM, supporting interventional medicine, particularly in optimizing radioembolization therapy. Established in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, Mirada Medical sells its solutions through direct sales and distribution channels, focusing on integrating advanced technology with practical applications for the diagnosis and treatment of cancer and other diseases.

CrestOptics is a company specializing in the development and manufacture of advanced systems for fluorescence microscopy. Based in Rome, Italy, the firm leverages its proximity to renowned research institutions to foster collaboration on innovative projects, including partnerships with organizations like CNR – FISBAT. CrestOptics focuses on creating high-performance microscopy instruments that utilize optical and electrooptical technology, enhancing sensitivity, image quality, and clarity for both scientific and industrial applications. The company also benefits from the expertise of its partner, Crisel Instruments, which has over 15 years of experience in live cell imaging systems. Through its commitment to research and development, CrestOptics aims to provide state-of-the-art solutions tailored to the needs of the research community and various industrial sectors.

i2a SA is a diagnostic and medical informatics company based in Montpellier, France, specializing in microbiology. Established in 1988 by three engineers from Polytechnique, the company manufactures and markets instruments, software, and reagents tailored for microbiology laboratories and infection prevention services, primarily in Europe and North America. i2a's product lineup includes the Sirscan2000, an automatic reader for disc diffusion susceptibility tests, and various software solutions designed for monitoring susceptibility tests and epidemiological data. The company also provides essential reagents for bacteriology, such as rapid susceptibility test media and antibiotic discs. i2a is particularly notable for its strong presence in France, where it supplies around 75% of hospitals, and aims to expand its international reach in the coming years. By consistently adapting its products to meet user needs, i2a enhances its development potential and innovation within the field of microbiology.

1MED is a full service CRO offering clinical research services and solutions for all clinical trials' needs.

Emblation specializes in medical microwave technology, focusing on the development and commercialization of innovative solutions for the oncology, dermatology, and podiatry sectors. The company designs and manufactures microwave-based products aimed at treating various skin conditions and associated health issues. Their technology is centered on the precise destruction of tissue and the immune activation effects of microwave treatments, enhancing the capabilities of healthcare professionals in delivering effective patient care. Emblation’s offerings support advancements in medical research and product development, contributing to improved treatment protocols in their targeted fields.

Archway Dental Practice Limited, established in 1996 and located in Dursley, United Kingdom, offers a range of dental services primarily to private patients in the Dursley and Stroud areas. With over 15 years of experience, the practice provides high-quality dental care, including surgical procedures, diagnostics, and screening services. As of September 3, 2019, Archway Dental Practice operates as a subsidiary of Riverdale Healthcare Limited.

Mirada Medical Limited is a developer of medical imaging software applications, enhancing patient outcomes in radiology, molecular imaging, radiation oncology, and multidisciplinary meetings across hospitals, imaging centers, and cancer centers. The company offers several key products, including Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which provides automated organ-at-risk contouring services; and Mirada IM, supporting interventional medicine, particularly in optimizing radioembolization therapy. Established in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, Mirada Medical sells its solutions through direct sales and distribution channels, focusing on integrating advanced technology with practical applications for the diagnosis and treatment of cancer and other diseases.

Riverdale Healthcare is a new dentistry investment group to provide high quality, ethical dentistry.

OrthoD is a specialist manufacturer and distributor of medical products and implants for joint reconstruction, sport medicine, surgical products and infection control applications.

Swanton, a specialist provider of residential and supported living care for adults with complex learning disabilities, mental health disorders and acquired brain injuries. Swanton operates 24 specialist residential care homes, providing 259 registered beds across East Anglia, The West Midlands and South West Wales, the North East and Scotland. Swanton also provides a growing supported living service in its key localities. The company employs around 780 people and generated £25m revenues in the year end.

NIMGenetics es un Centro de Diagnóstico analítico con unidad de Genética autorizado por la Consejería de Sanidad de la Comunidad de Madrid. Nuestro equipo científico-médico acreditado profesional y científicamente por la Asociación Española de Genética Humana, está especializado en el desarrollo y aplicación de sistemas genómicos de alta resolución, para la realización de un diagnóstico clínico fiable y preciso.

Complete Care provides high acuity care at home to around 150 individuals with on-going complex clinical healthcare needs. The business employs around 650 personal care assistants (including registered nurses). This acquisition will complement Mitie’s existing domiciliary care operations in England and Wales, which are primarily operated through MiHomecare.

MiHomecare offers a comprehensive range of homecare services designed to assist individuals who require support due to age, illness, disability, or other health challenges. The company focuses on enabling clients to maintain their independence within their own homes. Its services include personal care, medication assistance, meal preparation, and light housekeeping. Additionally, MiHomecare provides live-in care, ensuring clients receive personalized attention and companionship. The company also specializes in complex care services, catering to those with more intricate health needs.

Enara provides high quality home care in the UK, delivering a wide range of services to people who require help and support due to illness, disability or infirmity. The business cares for people via local authority, NHS and private pay agreements.

Medical Imaging Partnership has been created by UK Radiologists to offer high-quality radiology services to both Private and NHS Patients. Medical Imaging Partnership's goal is to give both Patients and Referrers fast access to expert-led services. Medical Imaging Partnership offers an unparalleled service to Healthcare Professionals and Patients with reports by leading specialist Radiologists. Medical Imaging Partnership is accredited by all of the major private medical insurers and offer a competitive self-pay price.

Cancer Partners UK provides the highest levels of patient-focused care across a network of conveniently located, purpose-built cancer centres. Each centre has been individually designed to meet the needs of the local area and falls into one of three centre types. As such, each varies in what services are offered, but each centre aspires to the same core principles and provides the same high quality standard of patient services. From the moment a patient is referred by their GP, they have prompt access to diagnostic procedures and tests, as well as treatments including advanced radiotherapy, chemotherapy and hormone therapy, all ‘under one roof’.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Ulthera is a medical technology company based in Mesa, Arizona, specializing in ultrasound-based devices for aesthetic procedures. The company focuses on noninvasive techniques for skin rejuvenation, aiming to deliver safe and effective results in the growing market for energy-based therapies. The Ulthera® System utilizes patented DeepSEE™ technology, which combines imaging and therapeutic capabilities of ultrasound to meet the needs of the aesthetic industry. Originally conceived for image-guided cancer therapy, Ulthera has evolved over several years to address the demand for advanced elective medical procedures.

Convergence Pharmaceuticals is an independent biotechnology company established in October 2010 after acquiring specific neuroscience clinical assets from GlaxoSmithKline. The company specializes in the development of innovative analgesics, focusing on small molecule sodium channel blockers designed to address neuropathic pain. Its pipeline includes differentiated clinical-stage compounds that target key points in chronic pain signaling through the modulation of specific ion channels, aiming to achieve favorable efficacy, responder rates, and side effect profiles.

SureCalm Healthcare is dedicated to delivering high-quality homecare services for patients managing long-term chronic conditions. The company specializes in providing stoma care and continence devices, along with home delivery and personalized care services. Additionally, SureCalm has recently launched an internet and mail order pharmacy, which offers clients a comprehensive range of medication and related advice. By focusing on these essential services, SureCalm Healthcare aims to support patients in their daily health management within the comfort of their own homes.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PharmaKodex is a pharmaceutical company that develops and commercializes small molecule drugs for treating pain and neurological conditions. The company was founded in 2006 and is based in Cambridge, the United Kingdom with an additional office in Chippenham, the United Kingdom. As of February 23, 2009, PharmaKodex Ltd. operates as a subsidiary of Orexo AB.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.